Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Improving In Vivo Brain Delivery of Monoclonal Antibody Using Novel Cyclic Peptides.

Ulapane KR, Kopec BM, Siahaan TJ.

Pharmaceutics. 2019 Oct 31;11(11). pii: E568. doi: 10.3390/pharmaceutics11110568.

2.

In Vivo Brain Delivery and Brain Deposition of Proteins with Various Sizes.

Ulapane KR, Kopec BM, Siahaan TJ.

Mol Pharm. 2019 Nov 12. doi: 10.1021/acs.molpharmaceut.9b00763. [Epub ahead of print]

PMID:
31664837
3.

Validation of Cadherin HAV6 Peptide in the Transient Modulation of the Blood-Brain Barrier for the Treatment of Brain Tumors.

Sajesh BV, On NH, Omar R, Alrushaid S, Kopec BM, Wang WG, Sun HD, Lillico R, Lakowski TM, Siahaan TJ, Davies NM, Puno PT, Vanan MI, Miller DW.

Pharmaceutics. 2019 Sep 17;11(9). pii: E481. doi: 10.3390/pharmaceutics11090481.

4.

Orf239342 from the mushroom Agaricus bisporus is a mannose binding protein.

Rachmawati H, Sundari S, Nabila N, Tandrasasmita OM, Amalia R, Siahaan TJ, Tjandrawinata RR, Ismaya WT.

Biochem Biophys Res Commun. 2019 Jul 12;515(1):99-103. doi: 10.1016/j.bbrc.2019.05.107. Epub 2019 May 23.

PMID:
31128918
5.

Methotrexate disposition, anti-folate activity and efficacy in the collagen-induced arthritis mouse model.

Singh RK, van Haandel L, Kiptoo P, Becker ML, Siahaan TJ, Funk RS.

Eur J Pharmacol. 2019 Jun 15;853:264-274. doi: 10.1016/j.ejphar.2019.03.052. Epub 2019 Apr 2.

PMID:
30951714
6.

Protein PEGylation for cancer therapy: bench to bedside.

Gupta V, Bhavanasi S, Quadir M, Singh K, Ghosh G, Vasamreddy K, Ghosh A, Siahaan TJ, Banerjee S, Banerjee SK.

J Cell Commun Signal. 2019 Sep;13(3):319-330. doi: 10.1007/s12079-018-0492-0. Epub 2018 Nov 29. Review.

7.

Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases.

Moral MEG, Siahaan TJ.

Curr Top Med Chem. 2017;17(32):3425-3443. doi: 10.2174/1568026618666180118154514. Review.

8.

Peptides and Drug Delivery.

Ulapane KR, Kopec BM, Moral MEG, Siahaan TJ.

Adv Exp Med Biol. 2017;1030:167-184. doi: 10.1007/978-3-319-66095-0_8.

PMID:
29081054
9.

Improving Brain Delivery of Biomolecules via BBB Modulation in Mouse and Rat: Detection using MRI, NIRF, and Mass Spectrometry.

Ulapane KR, On N, Kiptoo P, Williams TD, Miller DW, Siahaan TJ.

Nanotheranostics. 2017;1(2):217-231. doi: 10.7150/ntno.19158. Epub 2017 Jun 8.

10.

Pulmonary Administration of Soluble Antigen Arrays Is Superior to Antigen in Treatment of Experimental Autoimmune Encephalomyelitis.

Kuehl C, Thati S, Sullivan B, Sestak J, Thompson M, Siahaan T, Berkland C.

J Pharm Sci. 2017 Nov;106(11):3293-3302. doi: 10.1016/j.xphs.2017.06.008. Epub 2017 Jun 15.

11.

Synthesis of a Bifunctional Peptide Inhibitor-IgG1 Fc Fusion That Suppresses Experimental Autoimmune Encephalomyelitis.

White DR, Khedri Z, Kiptoo P, Siahaan TJ, Tolbert TJ.

Bioconjug Chem. 2017 Jul 19;28(7):1867-1877. doi: 10.1021/acs.bioconjchem.7b00175. Epub 2017 Jun 22.

12.

Endotoxaemia-augmented murine venous thrombosis is dependent on TLR-4 and ICAM-1, and potentiated by neutropenia.

Obi AT, Andraska E, Kanthi Y, Kessinger CW, Elfline M, Luke C, Siahaan TJ, Jaffer FA, Wakefield TW, Henke PK.

Thromb Haemost. 2017 Jan 26;117(2):339-348. doi: 10.1160/TH16-03-0218. Epub 2016 Dec 15.

13.

Gram-Negative Pneumonia Alters Large-Vein Cell-Adhesion Molecule Profile and Potentiates Experimental Stasis Venous Thrombosis.

Obi AT, Andraska E, Kanthi Y, Luke CE, Elfline M, Madathilparambil S, Siahaan TJ, Jaffer FA, Wakefield TW, Raghavendran K, Henke PK.

J Vasc Res. 2016;53(3-4):186-195. Epub 2016 Oct 22.

14.

Comparison of Linear and Cyclic His-Ala-Val Peptides in Modulating the Blood-Brain Barrier Permeability: Impact on Delivery of Molecules to the Brain.

Alaofi A, On N, Kiptoo P, Williams TD, Miller DW, Siahaan TJ.

J Pharm Sci. 2016 Feb;105(2):797-807. doi: 10.1016/S0022-3549(15)00188-4.

15.

Probing the interaction between cHAVc3 peptide and the EC1 domain of E-cadherin using NMR and molecular dynamics simulations.

Alaofi A, Farokhi E, Prasasty VD, Anbanandam A, Kuczera K, Siahaan TJ.

J Biomol Struct Dyn. 2017 Jan;35(1):92-104. doi: 10.1080/07391102.2015.1133321. Epub 2016 Apr 12.

16.

Brain Delivery of Drug and MRI Contrast Agent: Detection and Quantitative Determination of Brain Deposition of CPT-Glu Using LC-MS/MS and Gd-DTPA Using Magnetic Resonance Imaging.

Tabanor K, Lee P, Kiptoo P, Choi IY, Sherry EB, Eagle CS, Williams TD, Siahaan TJ.

Mol Pharm. 2016 Feb 1;13(2):379-90. doi: 10.1021/acs.molpharmaceut.5b00607. Epub 2016 Jan 6.

17.

Cleaved thin-film probes for scanning tunneling microscopy.

Siahaan T, Kurnosikov O, Barcones B, Swagten HJ, Koopmans B.

Nanotechnology. 2016 Jan 22;27(3):03LT01. doi: 10.1088/0957-4484/27/3/03LT01. Epub 2015 Dec 4.

PMID:
26636763
18.

A Tribute to Ronald T. Borchardt--Teacher, Mentor, Scientist, Colleague, Leader, Friend, and Family Man.

Schowen KB, Schowen RL, Borchardt SE, Borchardt PM, Artursson P, Audus KL, Augustijns P, Nicolazzo JA, Raub TJ, Schöneich C, Siahaan TJ, Takakura Y, Thakker DR, Wolfe MS.

J Pharm Sci. 2016 Feb;105(2):370-385. doi: 10.1002/jps.24687. Epub 2016 Jan 29. No abstract available.

PMID:
26453244
19.

Bifunctional Peptide Inhibitors Suppress Interleukin-6 Proliferation and Ameliorates Murine Collagen-Induced Arthritis.

Büyüktimkin B, Kiptoo P, Siahaan TJ.

J Clin Cell Immunol. 2014 Dec;5(6). pii: 1000273.

21.

Influence of particle size, an elongated particle geometry, and adjuvants on dendritic cell activation.

Mathaes R, Winter G, Siahaan TJ, Besheer A, Engert J.

Eur J Pharm Biopharm. 2015 Aug;94:542-9. doi: 10.1016/j.ejpb.2015.06.015. Epub 2015 Jun 26.

PMID:
26118563
22.

Modulation of intercellular junctions by cyclic-ADT peptides as a method to reversibly increase blood-brain barrier permeability.

Laksitorini MD, Kiptoo PK, On NH, Thliveris JA, Miller DW, Siahaan TJ.

J Pharm Sci. 2015 Mar;104(3):1065-75. doi: 10.1002/jps.24309. Epub 2015 Jan 12.

23.

Routes of administration and dose optimization of soluble antigen arrays in mice with experimental autoimmune encephalomyelitis.

Thati S, Kuehl C, Hartwell B, Sestak J, Siahaan T, Forrest ML, Berkland C.

J Pharm Sci. 2015 Feb;104(2):714-21. doi: 10.1002/jps.24272. Epub 2014 Dec 1.

24.

Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers.

Laksitorini M, Prasasty VD, Kiptoo PK, Siahaan TJ.

Ther Deliv. 2014 Oct;5(10):1143-63. doi: 10.4155/tde.14.67. Review.

25.

Co-delivery of autoantigen and b7 pathway modulators suppresses experimental autoimmune encephalomyelitis.

Northrup L, Sestak JO, Sullivan BP, Thati S, Hartwell BL, Siahaan TJ, Vines CM, Berkland C.

AAPS J. 2014 Nov;16(6):1204-13. doi: 10.1208/s12248-014-9671-y. Epub 2014 Oct 9.

26.

Structure, size, and solubility of antigen arrays determines efficacy in experimental autoimmune encephalomyelitis.

Sestak JO, Fakhari A, Badawi AH, Siahaan TJ, Berkland C.

AAPS J. 2014 Nov;16(6):1185-93. doi: 10.1208/s12248-014-9654-z. Epub 2014 Sep 6.

27.

(1)H, (13)C and (15)N backbone assignment of the EC-1 domain of human E-cadherin.

Prasasty VD, Krause ME, Tambunan US, Anbanandam A, Laurence JS, Siahaan TJ.

Biomol NMR Assign. 2015 Apr;9(1):31-5. doi: 10.1007/s12104-013-9539-6. Epub 2014 Feb 8.

28.

Modulation of blood-brain barrier permeability in mice using synthetic E-cadherin peptide.

On NH, Kiptoo P, Siahaan TJ, Miller DW.

Mol Pharm. 2014 Mar 3;11(3):974-81. doi: 10.1021/mp400624v. Epub 2014 Feb 19.

29.

Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitis.

Sestak JO, Sullivan BP, Thati S, Northrup L, Hartwell B, Antunez L, Forrest ML, Vines CM, Siahaan TJ, Berkland C.

Mol Ther Methods Clin Dev. 2014 Apr 9;1:14008. doi: 10.1038/mtm.2014.8. eCollection 2014.

30.

Hyaluronic acid graft polymers displaying peptide antigen modulate dendritic cell response in vitro.

Chittasupho C, Sestak J, Shannon L, Siahaan TJ, Vines CM, Berkland C.

Mol Pharm. 2014 Jan 6;11(1):367-73. doi: 10.1021/mp4003909. Epub 2013 Dec 4.

31.

Suppression of MOG- and PLP-induced experimental autoimmune encephalomyelitis using a novel multivalent bifunctional peptide inhibitor.

Badawi AH, Siahaan TJ.

J Neuroimmunol. 2013 Oct 15;263(1-2):20-7. doi: 10.1016/j.jneuroim.2013.07.009. Epub 2013 Aug 1.

32.

Single-step grafting of aminooxy-peptides to hyaluronan: a simple approach to multifunctional therapeutics for experimental autoimmune encephalomyelitis.

Sestak J, Mullins M, Northrup L, Thati S, Forrest ML, Siahaan TJ, Berkland C.

J Control Release. 2013 Jun 28;168(3):334-40. doi: 10.1016/j.jconrel.2013.03.015. Epub 2013 Mar 27.

33.

Controlling immune response and demyelination using highly potent bifunctional peptide inhibitors in the suppression of experimental autoimmune encephalomyelitis.

Kiptoo P, Büyüktimkin B, Badawi AH, Stewart J, Ridwan R, Siahaan TJ.

Clin Exp Immunol. 2013 Apr;172(1):23-36. doi: 10.1111/cei.12029.

34.

Vaccinelike and prophylactic treatments of EAE with novel I-domain antigen conjugates (IDAC): targeting multiple antigenic peptides to APC.

Büyüktimkin B, Manikwar P, Kiptoo PK, Badawi AH, Stewart JM Jr, Siahaan TJ.

Mol Pharm. 2013 Jan 7;10(1):297-306. doi: 10.1021/mp300440x. Epub 2012 Nov 29.

35.

Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Badawi AH, Siahaan TJ.

Clin Immunol. 2012 Aug;144(2):127-38. doi: 10.1016/j.clim.2012.05.010. Epub 2012 Jun 5. Review.

36.

Methotrexate (MTX)-cIBR conjugate for targeting MTX to leukocytes: conjugate stability and in vivo efficacy in suppressing rheumatoid arthritis.

Majumdar S, Anderson ME, Xu CR, Yakovleva TV, Gu LC, Malefyt TR, Siahaan TJ.

J Pharm Sci. 2012 Sep;101(9):3275-91. doi: 10.1002/jps.23164. Epub 2012 Apr 26.

37.

Improving the stability of the EC1 domain of E-cadherin by thiol alkylation of the cysteine residue.

Trivedi M, Laurence JS, Williams TD, Middaugh CR, Siahaan TJ.

Int J Pharm. 2012 Jul 15;431(1-2):16-25. doi: 10.1016/j.ijpharm.2012.03.051. Epub 2012 Apr 17.

38.

Photonic crystal cavity on optical fiber facet for refractive index sensing.

Wang B, Siahaan T, Dündar MA, Nötzel R, van der Hoek MJ, He S, van der Heijden RW.

Opt Lett. 2012 Mar 1;37(5):833-5. doi: 10.1364/OL.37.000833.

PMID:
22378409
39.

Vaccine-like controlled-release delivery of an immunomodulating peptide to treat experimental autoimmune encephalomyelitis.

Büyüktimkin B, Wang Q, Kiptoo P, Stewart JM, Berkland C, Siahaan TJ.

Mol Pharm. 2012 Apr 2;9(4):979-85. doi: 10.1021/mp200614q. Epub 2012 Mar 13.

40.

I-domain-antigen conjugate (IDAC) for delivering antigenic peptides to APC: synthesis, characterization, and in vivo EAE suppression.

Manikwar P, Büyüktimkin B, Kiptoo P, Badawi AH, Galeva NA, Williams TD, Siahaan TJ.

Bioconjug Chem. 2012 Mar 21;23(3):509-17. doi: 10.1021/bc200580j. Epub 2012 Mar 12.

41.

Suppression of EAE and prevention of blood-brain barrier breakdown after vaccination with novel bifunctional peptide inhibitor.

Badawi AH, Kiptoo P, Wang WT, Choi IY, Lee P, Vines CM, Siahaan TJ.

Neuropharmacology. 2012 Mar;62(4):1874-81. doi: 10.1016/j.neuropharm.2011.12.013. Epub 2011 Dec 17.

42.

Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.

Chittasupho C, Siahaan TJ, Vines CM, Berkland C.

Ther Deliv. 2011 Jul;2(7):873-89. doi: 10.4155/tde.11.60. Review.

43.

Rapid identification of fluorochrome modification sites in proteins by LC ESI-Q-TOF mass spectrometry.

Manikwar P, Zimmerman T, Blanco FJ, Williams TD, Siahaan TJ.

Bioconjug Chem. 2011 Jul 20;22(7):1330-6. doi: 10.1021/bc100560c. Epub 2011 Jun 7.

44.

Utilization of I-domain of LFA-1 to Target Drug and Marker Molecules to Leukocytes.

Manikwar P, Tejo BA, Shinogle H, Moore DS, Zimmerman T, Blanco F, Siahaan TJ.

Theranostics. 2011;1:277-89. Epub 2011 May 10.

45.

Calcium condensed LABL-TAT complexes effectively target gene delivery to ICAM-1 expressing cells.

Khondee S, Baoum A, Siahaan TJ, Berkland C.

Mol Pharm. 2011 Jun 6;8(3):788-98. doi: 10.1021/mp100393j. Epub 2011 Apr 22.

46.

Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases.

Manikwar P, Kiptoo P, Badawi AH, Büyüktimkin B, Siahaan TJ.

Med Res Rev. 2012 Jul;32(4):727-64. doi: 10.1002/med.20243. Epub 2011 Mar 23. Review.

47.

Nanoparticles targeting dendritic cell surface molecules effectively block T cell conjugation and shift response.

Chittasupho C, Shannon L, Siahaan TJ, Vines CM, Berkland C.

ACS Nano. 2011 Mar 22;5(3):1693-702. doi: 10.1021/nn102159g. Epub 2011 Mar 4.

48.

Enhancement of drug absorption through the blood-brain barrier and inhibition of intercellular tight junction resealing by E-cadherin peptides.

Kiptoo P, Sinaga E, Calcagno AM, Zhao H, Kobayashi N, Tambunan US, Siahaan TJ.

Mol Pharm. 2011 Feb 7;8(1):239-49. doi: 10.1021/mp100293m. Epub 2010 Dec 17.

49.

Controlling ligand surface density optimizes nanoparticle binding to ICAM-1.

Fakhari A, Baoum A, Siahaan TJ, Le KB, Berkland C.

J Pharm Sci. 2011 Mar;100(3):1045-56. doi: 10.1002/jps.22342. Epub 2010 Oct 4.

50.

Peptide-mediated targeted drug delivery.

Majumdar S, Siahaan TJ.

Med Res Rev. 2012 May;32(3):637-58. doi: 10.1002/med.20225. Epub 2010 Sep 2. Review.

PMID:
20814957

Supplemental Content

Loading ...
Support Center